News

The pioneer in neuroimmune research and itch physiology discusses how treatment innovation has evolved dermatology—and what still needs to be changed in practice.

In this interview at AAD 2024, Porter discusses recent data from the SUNSHINE and SUNRISE trials on secukinumab for patients with HS.

Phototherapy is consistently beneficial for patient-reported and clinical outcomes regardless of the location, according to late-breaking data at AAD 2024.

Data from the phase 2 KNOCKOUT study show risankizumab's sustained benefit in reducing memory cells over 52 weeks in psoriasis patients.

In late-breaking data from AAD 2024, treatment with the JNJ-2113 targeted oral peptide led to several notable findings regarding patients with moderate-to-severe psoriasis.

Hamzavi discusses new late-breaking data from AAD 2024, including major takeaways and safety profile after 52 weeks.

These findings from AAD 2024 did not include statistically significant infliximab response predictors, though it had been the largest reported cohort on the subject to date.

A national cohort analysis presented at AAD 2024 showed a significant link between maternal HS exposure and poor health outcomes among children.

In this new analysis presented at AAD 2024, patients with HS saw substantial improvements in their hidradenitis suppurativa-related pain following treatment with bimekizumab.

A new analysis of the phase 3 ADORING 3 extension trial involved a large, diverse population and the analysis showed that 91% of eligible participants from previous phases rolled over into this trial.

Lio reviews a field now teeming with FDA-approved options and candidates throughout early-age eczema, psoriasis and more.

Published one-year results from PULSAR and PHOTON show extended dosing regimens with aflibercept 8 mg were non-inferior to aflibercept 2 mg for treating wet AMD and DME.

Take our latest 5-question quiz based on the recommended strategies of laboratory-based diagnosis of epidermolysis bullosa.

On March 08, 2024, the FDA approved semaglutide 2.4 mg (Wegovy) to reduce cardiovascular risk in adults with obesity or overweight and heart disease based on the SELECT trial.

New data presented at AAD 2024 highlights challenges in financial status, insurance and comorbidities among black pediatric patients with HS.

In phase 4 data from the IMMpulse study, presented at AAD 2024, comparisons in efficacy were highlighted between risankizumab and apremilast for psoriasis patients eligible for systemic therapy.

In this discussion, Jonathan Silverberg described his team’s new phase 3 findings presented at AAD 2024 regarding upadacitinib and its impact on minimal disease activity in eczema patients.

James Q. Del Rosso, DO, discusses the recent report of benzene risk in benzoyl peroxide, as well as the need for active antibiotic monitoring in dermatology.

An analysis of the Strong Heart Family Study details High rates of dyslipidemia in American Indian youth and young adults, with more than 70% of those 15-39 years old affected.

In an interview with HCPLive, Viktoriya Karakcheyeva, MD, discussed how women healthcare workers experience more burnout than their male colleagues.

Results of the systematic review point to significant evidence gaps in most cardiovascular risk management interventions for patients with CKD, especially those with stages 4 to 5.

With drug breakthroughs reaching epidermolysis bullosa, Paller considers what may come next for other rare skin diseases.

The study found being underweight was linked to age-related hearing loss for males, but for females, both underweight and obese were linked to hearing loss.

Curative DAA therapy did not completely normalize immune activation and inflammatory biomarkers in individuals with a history of injection drug use and HCV infection.

A recap of the questions and top comments from our March 04, 2024, pre-AAD LinkedIn Chat highlighting the American Academy of Dermatology's 2024 annual meeting.

Lawrence Eichenfield, MD, reviews prescription and at-home care strategies for pediatric atopic dermatitis, as well as the best measures of disease monitoring.

Jon Martin, US Commercial Lead of Biosimilars at Organon, discusses the decision to select biosimilar adalimumab-bwwd and its potential implications on the pharmaceutical market.

Continuous glucose monitoring was associated with lower odds of diabetic retinopathy development, even after adjusting for hemoglobin A1c levels.